Benzbromarone is a uricosuric used to treat asymptomatic and symptomatic hyperuricemia, gout.

Benzbromarone lowers serum uric acid concentrations and increases urinary urate excretion, probably by inhibition of proximal renal tubular urate reabsorption with no effect on uric acid synthesis.

Bioavailability: 50%(oral); Initial uricosuric effects: 3hrs (oral); Peak uricosuric effects: 8-12hrs. Protein Binding: greater than 99%, Volume of Distribution: 19L. Metabolism Sites- LIVER, extensive. Renal Excretion: 18%, FECES, 50% to 82%. Elimination half-life: 2 to 4 hours

Renal dysfunction, glomerular filtration rate is less than 20ml/minute; Benzbromarone therapy should not be initiated during an acute attack of gout.

Avoided

Avoided

Diarrhea, rash; benzbromarone may precipitate an acute attack of gout and/or uric acid nephropathy. Ensure adequate fluid intake and maintenance of a relatively high urine pH to reduce the risk of nephrolithiasis.

50-200 mg QD